MucoLife Therapeutics secures investment and partners with US-based Health Wildcatters Accelerator to advance a first-in-class treatment for COPD
..............................................................
GU Ventures sprider nyheter och information kring verksamheten, sina bolag, samt alumnibolag:
..............................................................
MucoLife Therapeutics, a Swedish biotech company developing pioneering drugs for Chronic obstructive pulmonary disease (COPD), announces a partnership with the US-based life science accelerator Health Wildcatters. Out of nearly 700 applications, MucoLife Therapeutics was one of ten startups chosen to participate in the Health Wildcatters program.
"The partnership with Health Wildcatters is a significant recognition of our technology and the potential of our drug candidate MLT-001 for COPD," says Dr. Thaher Pelaseyed, co-founder and CEO of MucoLife Therapeutics. "Our collaboration will provide a great opportunity to build relations with major US investors to accelerate the development of our groundbreaking drug to combat COPD."
"Our technology is unique and has the potential to revolutionize the treatment of COPD, a complex lung disease," says Prof. Gunnar C. Hansson, co-founder and Chief scientific officer at MucoLife Therapeutics. "With the support of Health Wildcatters, we are taking a major step towards human clinical trials."
Health Wildcatters, one of the largest US accelerator programs, offers MucoLife Therapeutics unique access to experts and investors in the US life science sector.
"We're excited to welcome our first Swedish startup into our accelerator", said Dr. Hubert Zajicek, CEO of Health Wildcatters. "COPD is one of the leading causes of death in the US and worldwide. Improving the lives of people living with COPD is a noble cause and we are looking forward to playing a small role in helping MucoLife bring its solution to clinical trials", he said.
MucoLife Therapeutics' drug candidate MLT-001 results from 40 years of research at the Mucin Biology Group, a world-leading research center at the University of Gothenburg. GU Ventures has been involved in the company's establishment from the start.
"We are incredibly proud of MucoLife Therapeutics and their success," says Klementina Österberg, CEO of GU Ventures. "This is a fantastic example of how Swedish life science research can achieve global impact."
About MucoLife Therapeutics
MucoLife Therapeutics pioneers a novel approach for treating mucus obstruction in COPD. MLT-001 is the company’s first-in-class product that dissolves mucus plugs in the airways, thereby improving lung function and preventing inflammation and infections.
About Health Wildcatters
Health Wildcatters is a top-ranked seed accelerator based in Dallas, TX. Exclusively focused on healthcare, Health Wildcatters has 109 portfolio companies that have raised collectively over $300 million across the last eleven years.
Press contact MucoLife Therapeutics
Thaher Pelaseyed
Co-founder & CEO
tpelaseyed@mucolife.com
www.mucolife.com
Press contact Health Wildcatters
Jovelyn Castellanos
jovelyn@healthwildcatters.com
www.healthwildcatters.com